Collegium Pharmaceutical, Inc. Business Acquisition, Pro Forma Net Income (Loss)
Collegium Pharmaceutical, Inc. (COLL) reported Business Acquisition, Pro Forma Net Income (Loss) of -$15.80 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2025-02-27
- Collegium Pharmaceutical, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2024-12-31 was -$51.77M.
- Collegium Pharmaceutical, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2024-09-30 was $5.39M, a 53.40% decline year-over-year.
- Collegium Pharmaceutical, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2023-12-31 was -$206.99M.
- Collegium Pharmaceutical, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2023-09-30 was $11.57M.
- Collegium Pharmaceutical, Inc. business acquisition, pro forma net income (loss) for fiscal 2024 was -$15.80M.
- Collegium Pharmaceutical, Inc. business acquisition, pro forma net income (loss) for fiscal 2023 was -$104.14M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$51.77M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$46.38M derived: sum of 2 quarters · filed 2025-02-27 | -$15.80M 10-K · filed 2025-02-27 | |
| 2024-09-30 | $5.39M 10-Q · filed 2024-11-07 | $35.97M 10-Q · filed 2024-11-07 | ||
| 2023-12-31 | -$206.99M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$195.42M derived: sum of 2 quarters · filed 2025-02-27 | -$104.14M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $11.57M 10-Q · filed 2024-11-07 | $102.85M 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |